The main objective of this study was to compare in vitro activities of a novel fluoroquinolone (FQ), UB-8902, with ofloxacin (OFX), levofloxacin (LFX), and moxifloxacin (MOX) against Mycobacterium tuberculosis isolates. Eleven OFX-resistant and 11 drug-susceptible clinical isolates were studied. Individual minimum inhibitory concentrations of OFX, LFX, MOX, and UB-8902 were determined using Middlebrook 7H11 agar. The concentrations studied ranged from 0.125 to 128 μg/mL in twofold dilutions. UB-8902 was more active than LFX and similar to MOX for OFX-resistant M. tuberculosis isolates. In addition, UB-8902 and MOX showed equal activity against drug-susceptible isolates, both being more active than OFX and LFX. In conclusion, the new FQ, UB-8902, showed good activity against OFX-resistant isolates. Moreover, it showed better activity than OFX and LFX and was equivalent to MOX against FQ-susceptible clinical isolates. UB-8902 can be considered as a drug with potential antituberculous activity, similar to MOX.
Get full access to this article
View all access options for this article.
References
1.
World Health Organization,. 2018. Global Tuberculosis Report 2018. WHO/CDS/TB/2018.20. WHO, Geneva.
TakiffH., and GuerreroE.. 2011. Current prospects for the fluoroquinolones as first-line tuberculosis therapy. Antimicrob. Agents. Chemother. 55:5421–5429.
4.
PrangerA.D., van der WerfT.S, KosterinkJ.G.W, and AlffenaarJ.W.C. 2019. The role of fluoroquinolones in the treatment of tuberculosis in 2019. Drugs, 79:161–171.
5.
GrinsburgA.S., GrossetJ.H, and BishaiW.R.. 2003. Fluoroquinolone, tuberculosis, and resistance. Lancet. Infect. Dis. 3:432–442.
6.
FabregaA., MadrugaS., GiraltE., and VilaJ.. 2009. Mechanism of action of and resistance to quinolones. Microbial Biotechnol. 2:40–61.
7.
VilaJ., Sanchez-CespedesJ., SierraJ.M, PiquerasM., NicolasE., FreixesJ., and GiraltE.. 2006. Antibacterial evaluation of a collection of norfloxacin and ciprofloxacino derivates against multiresistant bacteria. Int. J. Antimicrob. Agents, 28:19–24.
8.
López-RojasR., Sanchez-CespedesJ., Docobo-PerezF., Dominguez-HerreraJ., VilaJ., and PachonJ.. 2011. Pre-clinical Studies of a new quinolone (UB-8902) aganist Acinetobacter baumannii resistant to ciprofloxacino. Int. J. Antimicrob. Agents. 38:355–359.
9.
López-GavínA., TudóG., VergaraA., HurtadoJ.C, and Gonzalez-MartínJ.. 2015. In vitro activity against Mycobacterium tuberculosis of levofloxacin, moxifloxacin and UB-8902 in combination with clofazimine and pretomanid. Int. J. Antimicrob. Agents, 46:582–585.
10.
World Health Organization. 2018. Technical Manual for Drug Susceptibility Testing of Medicines Used in the Treatment of Tuberculosis. WHO/CDS/TB/2018.24. WHO, Geneva.
11.
TakiffH.E., SalazalL., GuerreroC., PhilippW., HuangW.M, KreiswirthB., ColeS.T, Jacobs JrW.R, and TelentiA.. 1994. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob. Agents. Chemother. 38:773–780.
12.
BallestaS., GarcíaI., Sánchez-CéspedesJ., VilaJ., and PascualA.. 2010. Intracellular penetration and activity of UB-8902 in human plymorphonuclear leuckocytes. Enferm. Infecc. Microbiol. Clin. 28:612–614.
13.
SreevatsanS., PanX., StockbauerK.E, ConnellN.D, KreiswithB.N, WhittamT.S, and MusserJ.M. 1997. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc. Natl. Acad. Sci. USA, 94:9869–9874.
14.
Almeida Da SilvaP.E., and PalominoJ.C.. 2011. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J. Antimicrob. Chemother. 66:1417–1430.
15.
AvalosE., CatanzaroD., CantanzaroA., GaniatsT., BrodineS., AlcarazJ., and RodwellT.. 2015. Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review. PLoS One, 10:e0120470.
16.
Von GrollA., MartinA., JureenP., HoffnerS., VandammeP., PortaelsF., PalominoJ.C, and da SilvaP.A.. 2009. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob. Agents. Chemother. 53:4498–4500.
17.
KocagozT., HackbarthC.J, UnsalI., RosenbergE.Y, NikaidoH., and ChambersH.F.. 1996. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob. Agents. Chemother. 40:1768–1774.
18.
CuiZ., WangJ., LuJ., HuangX., and ZhongyiH.. 2011. Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009. BMC Infect. Dis. 11:78.
